Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 783-790

  Ni, Lei ^a   Feng, Yun ^a   Wan, Huanying ^a   Ma, Qinyun ^a   Fan, Liang ^a   Qian, Yanrong ^a   Li, Qingyun ^a   Xiang, Yi ^a   Gao, Beili ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiotensin (1 7); MAPK; MMPs; Non small cell lung cancer; PI3K Akt

Indexed keywords

ANGIOTENSIN[1-7]; BETA ACTIN; GELATINASE A; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; METASTASIS INHIBITION; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ZYMOGRAPHY;

ADENOCARCINOMA; ANGIOTENSIN I; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 84863050999     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1554     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Erridge SC, Moller H, Price A and Brewster D: International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol 4: 570-577, 2007. (Pubitemid 47534756)
3. Santos RA, Ferreira AJ and Simões e Silva AC: Recent advances in the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis. Exp Physiol 93: 519-527, 2008.
4. Deshayes F and Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16: 293-299, 2005. (Pubitemid 41206635)
5. Lau ST and Leung PS: Role of the RAS in pancreatic cancer. Curr Cancer Drug Targets 11: 412-420, 2011.
6. Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han B, Xiang Y, Che J, Cao H, Fei X and Qiu W: The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep 23: 941-948, 2010.
7. Ferrario CM, Trask AJ and Jessup JA: Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290, 2005. (Pubitemid 41698533)
8. Santos RA, Simoes e Silva AC, Maric C, et al: Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263, 2003. (Pubitemid 36842532)
9. Gallagher PE and Tallant EA: Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25: 2045-2052, 2004. (Pubitemid 39534840)
10. Soto-Pantoja DR, Menon J, Gallagher PE and Tallant EA: Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 8: 1676-1683, 2009.
11. Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 70: 498-505, 2002.
12. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
13. Parks WC and Shapiro SD: Matrix metalloproteinases in lung biology. Respir Res 2: 10-19, 2001. (Pubitemid 34187902)
14. Thomas P and Khokha R: Diferential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190: 150-156, 2000. (Pubitemid 30082487)
15. Chakraborti S, Mandal M, Das S, Mandal A and Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253: 269-285, 2003.
16. Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403, 2003. (Pubitemid 36791895)
17. Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC and Lee IS: Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 354: 165-171, 2007. (Pubitemid 46123215)
18. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S and Ronai Z: Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11: 447-460, 2007. (Pubitemid 46670078)
19. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
20. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS and Chung J: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15: 1953-1962, 2001. (Pubitemid 32848799)
21. Sahai E: Illuminating the metastatic process. Nat Rev Cancer 7: 737-749, 2007.
22. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al: Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90: 1059-1068, 2004. (Pubitemid 38495829)
23. Zhou L, Zhang RF, Zhang LF, Yao WY, Li JS and Yuan YZ: Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett 307: 18-25, 2011.
24. Feng Y, Ni L, Wan H, et al: Overexpression of ACE2 has antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep 26: 1157-1164, 2011.
25. Noel A, Jost M and Maquoi E: Matrix metalloproteinases at cancer tumor - host interface. Semin Cell Dev Biol 19: 52-60, 2008. (Pubitemid 350235981)
26. Brew K, Dinakarpandian D and Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283, 2000. (Pubitemid 30119906)
27. Pan CH, Wen CH and Lin CS: Interplay of angiotensin II and angiotensin-(1-7) in the regulation of matrix metalloproteinases of human cardiocytes. Exp Physiol 93: 599-612, 2009. (Pubitemid 351595058)
28. Chien CS, Shen KH, Huang JS, Ko SC and Shih YW: Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 333: 169-180, 2009.
29. Nebreda AR and Porras A: p38 MAP kinases: beyond the stress response. Trends Biochem Sci 25: 257-260, 2000. (Pubitemid 30333380)
30. Kyriakis JM and Avruch J: Mammalian mitogen activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001. (Pubitemid 32267078)
31. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA and Gallagher PE: Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 67: 2809-2814, 2007.
32. Lever AF, Hole DJ and Gillis CR: Do inhibitors of angiotensin-I- converting enzyme protect against risk of cancer? Lancet 352: 179-184, 1998. (Pubitemid 28327802)
33. Christian JB, Lapane KL, Hume AL, Eaton CB and Weinstock MA: Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 100: 1223-1232, 2008.
34. Arafat HA, Gong Qk, Chipitsyna G, Rizvi A, Saa CT and Yeo CJ: Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204: 996-1005, 2007. (Pubitemid 46661215)
35. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R and Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135: 1429-1435, 2009.
36. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB and Ferrario CM: Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 14: 799-805, 1996. (Pubitemid 26187416)
37. Tallant EA, Ferrario CM and Gallagher PE: Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: 1560-1566, 2007.